Retatrutide Side Effects: Trial Data & Warnings 2026

01

The most common retatrutide side effects (from trials)

Like other incretin drugs, retatrutide's most frequently reported side effects in trials are gastrointestinal, and they are clearly dose-related — worst during the escalation weeks and mostly mild-to-moderate. The most complete picture comes from the Phase 3 TRIUMPH-1 obesity trial (80 weeks).

Per Eli Lilly's TRIUMPH-1 announcement, adverse events at the 12 mg dose versus placebo were:

(Source: Eli Lilly TRIUMPH-1 Phase 3 trial, 12 mg dose. Individual experience varies. Trials are not head-to-head with other drugs.)

The gastrointestinal events were mostly mild-to-moderate, dose-related, and worst during escalation.

The earlier Phase 2 trial published in the New England Journal of Medicine reported the same pattern, with GI effects rising alongside the dose.

Discontinuation for adverse events in TRIUMPH-1 also rose with dose: about 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg, versus 4.9% on placebo — so the highest dose that produced the greatest weight loss also produced the most dropouts for side effects.

02

Investigational status and what the trials showed

Retatrutide's weight-loss results are the reason it draws so much attention — but they come strictly from clinical trials of an unapproved drug.

These figures describe trial outcomes, not a promise of results for any individual, and they were achieved under close study supervision.

The ongoing program is registered publicly — for example, ClinicalTrials.gov NCT05929066.

The dysesthesia signal (retatrutide-specific)

One side effect stands out as unusual for this class: dysesthesia — abnormal or altered skin sensations (such as tingling or heightened sensitivity).

In TRIUMPH-1 it was reported by 12.5% at the 12 mg dose versus 0.9% on placebo, and it has been linked to the glucagon component of the triple agonist.

Because semaglutide and tirzepatide do not target glucagon in the same way, this signal is relatively specific to retatrutide among the widely studied incretin drugs.

The heart-rate signal (glucagon-driven)

Retatrutide's glucagon activity is also associated with a modest increase in resting heart rate — on average a few beats per minute in trials, which tended to ease over time. This was observed in the Phase 2 NEJM data and is another triple-agonist-specific signal that study teams monitored.

What this means for long-term cardiovascular safety is exactly the kind of question that the full Phase 3 program and regulatory review are designed to answer.

03

How long do retatrutide side effects last?

In trials, the common gastrointestinal side effects were mostly transient, easing after the escalation period as the body adjusted — the familiar incretin pattern seen across this drug class.

They were strongly dose-dependent: higher doses produced more nausea, diarrhea, constipation, and vomiting, and also the most discontinuations (11.3% at 12 mg versus 4.1% at 4 mg).

Study protocols used a slow, stepwise escalation — in Phase 2, starting at 2 mg and stepping up every 4 weeks — precisely because gradual dosing limits side effects.

Because retatrutide is investigational, there is no official public dosing schedule and no approved way to take it. Any dosing in trials is set and supervised by the study team — it is not something to replicate on your own.

04

What the trials monitored: safety signals to understand

Retatrutide is not approved, so no boxed warning or final FDA label exists yet. What follows is not prescribing information — it is a summary of the safety areas that trials and the GLP-1 drug class have flagged for close monitoring.

GLP-1 class thyroid signal (studied, not confirmed for retatrutide)

Approved GLP-1 and GIP/GLP-1 drugs carry an FDA boxed warning for thyroid C-cell tumors based on rodent findings, with human relevance unknown.

Because retatrutide acts on GLP-1 among its targets, this class-level signal is part of what regulators evaluate.

Any formal warning for retatrutide would only be established through the approval process — none exists today.

Gastrointestinal and dehydration risk

The dominant, expected effects are GI: nausea, diarrhea, constipation, and vomiting.

As with all incretin drugs, persistent vomiting or diarrhea raises the risk of dehydration, which study teams watch for.

Heart rate

As noted above, a modest resting heart-rate increase tied to the glucagon component was observed and monitored in trials.

Glucose effects

Because retatrutide affects metabolic hormones, trials monitor blood glucose; in people also taking glucose-lowering medicines, hypoglycemia risk is a standard monitoring area for this class.

If you are considering or enrolled in a retatrutide trial, your study team's guidance and the trial's informed-consent documents are the authoritative source on risks — not this page.

05

When to seek care in a trial: retatrutide red-flag table

(For trial participants — always follow your study team's instructions first.)

This table is a guide for trial participants, not a substitute for your study team's professional judgment.

06

Retatrutide vs tirzepatide: an extra hormone, extra signals

Retatrutide is frequently compared with tirzepatide (Mounjaro, Zepbound), an approved dual GIP/GLP-1 agonist.

The key difference is the third target — glucagon — which drives retatrutide's larger trial weight loss and its distinctive dysesthesia and heart-rate signals.

Note that tirzepatide is FDA-approved while retatrutide is not.

Trials are not head-to-head, so cross-drug numbers are indicative, not directly comparable.

For the approved dual agonist, see our tirzepatide side effects guide.

07

Availability by market

Retatrutide is not approved anywhere in the world. It is legally available only to participants in Eli Lilly's clinical trials, and it cannot be prescribed, purchased, or compounded. Anticipated regulatory submission is around 2026; if the trials and review are successful, the earliest realistic public availability would be roughly 2027–2028. Any product sold online as "retatrutide" outside a registered clinical trial is not an approved medicine, is not quality-assured, and may be unsafe and unlawful — this page does not endorse obtaining it that way.

To learn about legitimate trials, see ClinicalTrials.gov and speak with a licensed clinician.

08

Why HAVIT — Medication + Behavior Change, in One App

GLP-1 medications can meaningfully reduce weight — but the number on the scale is only part of the story.

Roughly 20–40% of the weight lost on GLP-1 therapy can come from lean (muscle) tissue rather than fat (Neeland et al., Diabetes, Obesity and Metabolism, 2024), and results tend to fade once the medication stops unless new habits take their place.

That's why leading guidance treats medication as one part of care, not the whole: the U.S. Preventive Services Task Force recommends that adults with obesity be offered intensive, multicomponent behavioral interventions (USPSTF, Grade B).

HAVIT is built for exactly this moment — one app that unites medication tracking, body composition, nutrition and protein, daily habit-building, and an AI coach that adapts to you.

Across our own 1,090 GLP-1 users, the most consistent trackers built the strongest habits (see the GLP-1 habit report).

Manage the medicine and the muscle — together. Start with HAVIT →

The most common retatrutide side effects (from trials)

Related articles